Harry Gelissen1, Harm-Jan de Grooth1,2, Yvo Smulders3, Evert-Jan Wils4, Wouter de Ruijter5, Roel Vink6, Bob Smit1,7, Jantine Röttgering1, Leila Atmowihardjo1, Armand Girbes1, Paul Elbers1, Pieter-Roel Tuinman1, Heleen Oudemans-van Straaten1, Angelique de Man1. 1. Department of Intensive Care Medicine, Research VUmc Intensive Care, Amsterdam Cardiovascular Science, Amsterdam Infection and Immunity Institute, Amsterdam Medical Data Science, Amsterdam UMC, location VUmc, Amsterdam, the Netherlands. 2. Department of Anesthesiology, Amsterdam UMC, location VUmc, Amsterdam, the Netherlands. 3. Department of Internal Medicine, Amsterdam UMC, location VUmc, Amsterdam, the Netherlands. 4. Department of Intensive Care, Franciscus Gasthuis & Vlietland, Rotterdam, the Netherlands. 5. Department of Intensive Care, Noordwest Ziekenhuisgroep, Alkmaar, the Netherlands. 6. Department of Intensive Care, Tergooiziekenhuizen, Hilversum, the Netherlands. 7. Department of Clinical Chemistry, HAGA Ziekenhuis, Den Haag, the Netherlands.
Abstract
Importance: Hyperoxemia may increase organ dysfunction in critically ill patients, but optimal oxygenation targets are unknown. Objective: To determine whether a low-normal Pao2 target compared with a high-normal target reduces organ dysfunction in critically ill patients with systemic inflammatory response syndrome (SIRS). Design, Setting, and Participants: Multicenter randomized clinical trial in 4 intensive care units in the Netherlands. Enrollment was from February 2015 to October 2018, with end of follow-up to January 2019, and included adult patients admitted with 2 or more SIRS criteria and expected stay of longer than 48 hours. A total of 9925 patients were screened for eligibility, of whom 574 fulfilled the enrollment criteria and were randomized. Interventions: Target Pao2 ranges were 8 to 12 kPa (low-normal, n = 205) and 14 to 18 kPa (high-normal, n = 195). An inspired oxygen fraction greater than 0.60 was applied only when clinically indicated. Main Outcomes and Measures: Primary end point was SOFARANK, a ranked outcome of nonrespiratory organ failure quantified by the nonrespiratory components of the Sequential Organ Failure Assessment (SOFA) score, summed over the first 14 study days. Participants were ranked from fastest organ failure improvement (lowest scores) to worsening organ failure or death (highest scores). Secondary end points were duration of mechanical ventilation, in-hospital mortality, and hypoxemic measurements. Results: Among the 574 patients who were randomized, 400 (70%) were enrolled within 24 hours (median age, 68 years; 140 women [35%]), all of whom completed the trial. The median Pao2 difference between the groups was -1.93 kPa (95% CI, -2.12 to -1.74; P < .001). The median SOFARANK score was -35 points in the low-normal Pao2 group vs -40 in the high-normal Pao2 group (median difference, 10 [95% CI, 0 to 21]; P = .06). There was no significant difference in median duration of mechanical ventilation (3.4 vs 3.1 days; median difference, -0.15 [95% CI, -0.88 to 0.47]; P = .59) and in-hospital mortality (32% vs 31%; odds ratio, 1.04 [95% CI, 0.67 to 1.63]; P = .91). Mild hypoxemic measurements occurred more often in the low-normal group (1.9% vs 1.2%; median difference, 0.73 [95% CI, 0.30 to 1.20]; P < .001). Acute kidney failure developed in 20 patients (10%) in the low-normal Pao2 group and 21 patients (11%) in the high-normal Pao2 group, and acute myocardial infarction in 6 patients (2.9%) in the low-normal Pao2 group and 7 patients (3.6%) in the high-normal Pao2 group. Conclusions and Relevance: Among critically ill patients with 2 or more SIRS criteria, treatment with a low-normal Pao2 target compared with a high-normal Pao2 target did not result in a statistically significant reduction in organ dysfunction. However, the study may have had limited power to detect a smaller treatment effect than was hypothesized. Trial Registration: ClinicalTrials.gov Identifier: NCT02321072.
Importance: Hyperoxemia may increase organ dysfunction in critically ill patients, but optimal oxygenation targets are unknown. Objective: To determine whether a low-normal Pao2 target compared with a high-normal target reduces organ dysfunction in critically ill patients with systemic inflammatory response syndrome (SIRS). Design, Setting, and Participants: Multicenter randomized clinical trial in 4 intensive care units in the Netherlands. Enrollment was from February 2015 to October 2018, with end of follow-up to January 2019, and included adult patients admitted with 2 or more SIRS criteria and expected stay of longer than 48 hours. A total of 9925 patients were screened for eligibility, of whom 574 fulfilled the enrollment criteria and were randomized. Interventions: Target Pao2 ranges were 8 to 12 kPa (low-normal, n = 205) and 14 to 18 kPa (high-normal, n = 195). An inspired oxygen fraction greater than 0.60 was applied only when clinically indicated. Main Outcomes and Measures: Primary end point was SOFARANK, a ranked outcome of nonrespiratory organ failure quantified by the nonrespiratory components of the Sequential Organ Failure Assessment (SOFA) score, summed over the first 14 study days. Participants were ranked from fastest organ failure improvement (lowest scores) to worsening organ failure or death (highest scores). Secondary end points were duration of mechanical ventilation, in-hospital mortality, and hypoxemic measurements. Results: Among the 574 patients who were randomized, 400 (70%) were enrolled within 24 hours (median age, 68 years; 140 women [35%]), all of whom completed the trial. The median Pao2 difference between the groups was -1.93 kPa (95% CI, -2.12 to -1.74; P < .001). The median SOFARANK score was -35 points in the low-normal Pao2 group vs -40 in the high-normal Pao2 group (median difference, 10 [95% CI, 0 to 21]; P = .06). There was no significant difference in median duration of mechanical ventilation (3.4 vs 3.1 days; median difference, -0.15 [95% CI, -0.88 to 0.47]; P = .59) and in-hospital mortality (32% vs 31%; odds ratio, 1.04 [95% CI, 0.67 to 1.63]; P = .91). Mild hypoxemic measurements occurred more often in the low-normal group (1.9% vs 1.2%; median difference, 0.73 [95% CI, 0.30 to 1.20]; P < .001). Acute kidney failure developed in 20 patients (10%) in the low-normal Pao2 group and 21 patients (11%) in the high-normal Pao2 group, and acute myocardial infarction in 6 patients (2.9%) in the low-normal Pao2 group and 7 patients (3.6%) in the high-normal Pao2 group. Conclusions and Relevance: Among critically ill patients with 2 or more SIRS criteria, treatment with a low-normal Pao2 target compared with a high-normal Pao2 target did not result in a statistically significant reduction in organ dysfunction. However, the study may have had limited power to detect a smaller treatment effect than was hypothesized. Trial Registration: ClinicalTrials.gov Identifier: NCT02321072.
Authors: Todd W Rice; Arthur P Wheeler; Gordon R Bernard; Douglas L Hayden; David A Schoenfeld; Lorraine B Ware Journal: Chest Date: 2007-06-15 Impact factor: 9.410
Authors: Rakshit Panwar; Miranda Hardie; Rinaldo Bellomo; Loïc Barrot; Glenn M Eastwood; Paul J Young; Gilles Capellier; Peter W J Harrigan; Michael Bailey Journal: Am J Respir Crit Care Med Date: 2016-01-01 Impact factor: 21.405
Authors: Olav L Schjørring; Thomas L Klitgaard; Anders Perner; Jørn Wetterslev; Theis Lange; Martin Siegemund; Minna Bäcklund; Frederik Keus; Jon H Laake; Matthew Morgan; Katrin M Thormar; Søren A Rosborg; Jannie Bisgaard; Annette E S Erntgaard; Anne-Sofie H Lynnerup; Rasmus L Pedersen; Elena Crescioli; Theis C Gielstrup; Meike T Behzadi; Lone M Poulsen; Stine Estrup; Jens P Laigaard; Cheme Andersen; Camilla B Mortensen; Björn A Brand; Jonathan White; Inge-Lise Jarnvig; Morten H Møller; Lars Quist; Morten H Bestle; Martin Schønemann-Lund; Maj K Kamper; Mathias Hindborg; Alexa Hollinger; Caroline E Gebhard; Núria Zellweger; Christian S Meyhoff; Mathias Hjort; Laura K Bech; Thorbjørn Grøfte; Helle Bundgaard; Lars H M Østergaard; Maria A Thyø; Thomas Hildebrandt; Bülent Uslu; Christoffer G Sølling; Nette Møller-Nielsen; Anne C Brøchner; Morten Borup; Marjatta Okkonen; Willem Dieperink; Ulf G Pedersen; Anne S Andreasen; Lone Buus; Tayyba N Aslam; Robert R Winding; Joerg C Schefold; Stine B Thorup; Susanne A Iversen; Janus Engstrøm; Maj-Brit N Kjær; Bodil S Rasmussen Journal: N Engl J Med Date: 2021-01-20 Impact factor: 176.079
Authors: Alexander Thomas; Sean van Diepen; Rachel Beekman; Shashank S Sinha; Samuel B Brusca; Carlos L Alviar; Jacob Jentzer; Erin A Bohula; Jason N Katz; Andi Shahu; Christopher Barnett; David A Morrow; Emily J Gilmore; Michael A Solomon; P Elliott Miller Journal: JACC Adv Date: 2022-08-26
Authors: Emanuele Rezoagli; Matteo Petrosino; Paola Rebora; David K Menon; Stefania Mondello; D James Cooper; Andrew I R Maas; Eveline J A Wiegers; Stefania Galimberti; Giuseppe Citerio Journal: Intensive Care Med Date: 2022-10-20 Impact factor: 41.787
Authors: Elena Crescioli; Thomas Lass Klitgaard; Lone Musaeus Poulsen; Bjørn Anders Brand; Martin Siegemund; Thorbjørn Grøfte; Frederik Keus; Ulf Gøttrup Pedersen; Minna Bäcklund; Johanna Karttunen; Matthew Morgan; Andrei Ciubotariu; Anne-Marie Gellert Bunzel; Stine Rom Vestergaard; Nicolaj Munch Jensen; Thomas Steen Jensen; Maj-Brit Nørregaard Kjær; Aksel Karl Georg Jensen; Theis Lange; Jørn Wetterslev; Anders Perner; Olav Lilleholt Schjørring; Bodil Steen Rasmussen Journal: Intensive Care Med Date: 2022-04-20 Impact factor: 41.787
Authors: Marta Martín-Fernández; María Heredia-Rodríguez; Paolo Pelosi; Jesús Villar; Eduardo Tamayo; Irene González-Jiménez; Mario Lorenzo-López; Estefanía Gómez-Pesquera; Rodrigo Poves-Álvarez; F Javier Álvarez; Pablo Jorge-Monjas; Juan Beltrán-DeHeredia; Eduardo Gutiérrez-Abejón; Francisco Herrera-Gómez; Gabriella Guzzo; Esther Gómez-Sánchez; Álvaro Tamayo-Velasco; Rocío Aller Journal: Crit Care Date: 2022-01-10 Impact factor: 9.097
Authors: Thijs A Lilien; Nina S Groeneveld; Faridi van Etten-Jamaludin; Mark J Peters; Corinne M P Buysse; Shawn L Ralston; Job B M van Woensel; Lieuwe D J Bos; Reinout A Bem Journal: JAMA Netw Open Date: 2022-01-04
Authors: Mervyn Singer; Paul J Young; John G Laffey; Pierre Asfar; Fabio Silvio Taccone; Markus B Skrifvars; Christian S Meyhoff; Peter Radermacher Journal: Crit Care Date: 2021-12-19 Impact factor: 9.097
Authors: Ekin Soydan; Gokhan Ceylan; Sevgi Topal; Pinar Hepduman; Gulhan Atakul; Mustafa Colak; Ozlem Sandal; Ferhat Sari; Utku Karaarslan; Dominik Novotni; Marcus J Schultz; Hasan Agin Journal: Front Med (Lausanne) Date: 2022-08-25